Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-023648
Filing Date
2025-08-14
Accepted
2025-08-13 21:45:43
Documents
60
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1086132
2 EX-31.1 ex31-1.htm EX-31.1 18126
3 EX-31.2 ex31-2.htm EX-31.2 18094
4 EX-32.1 ex32-1.htm EX-32.1 8519
5 EX-32.2 ex32-2.htm EX-32.2 8843
  Complete submission text file 0001641172-25-023648.txt   5770640

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cycc-20250630.xsd EX-101.SCH 46778
7 XBRL CALCULATION FILE cycc-20250630_cal.xml EX-101.CAL 45733
8 XBRL DEFINITION FILE cycc-20250630_def.xml EX-101.DEF 233678
9 XBRL LABEL FILE cycc-20250630_lab.xml EX-101.LAB 369979
10 XBRL PRESENTATION FILE cycc-20250630_pre.xml EX-101.PRE 277812
62 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 862608
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-50626 | Film No.: 251213887
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)